CryoLife competitors

I am the Chief Executive Officer, President and Chairman of Abiomed, Inc. (NASDAQ: ABMD), the only medical device company focused solely on heart recovery. At Abiomed, we are driven by our four principles: recovering hearts and saving lives, leading in technology and innovation, growing shareholder value and sustaining a winning culture of putting patients first. As a U.S. military veteran, I also serve as Co-Founder and Chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization committed to helping military veterans network with industry mentors to discover career opportunities in the life sciences industry.

Accredited public company director. Dynamic, creative, growth and success oriented leader. Proven experience building and leading an organization from distress to profitability while increasing shareholder value 5x in 24 months.

Michael F. Mahoney is a Director on the board of the Boys & Girls Club of Boston. He is the Chairman and CEO of Boston Scientific.

Michael A. Mussallem, age 56, has been chairman and CEO of Edwards Lifesciences, Inc. since 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter International Inc., including Group Vice President of its CardioVascular business from 1994 to 2000 and Group Vice President of the Biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the Chairman of Baxter's Asia Board overseeing Baxter's operations throughout Asia. Mr. Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics. He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. He received a bachelor's degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Indiana.

Timothy R. Wright is the President and CEO of M2Gen®. He was previously the Executive Vice President, Business Development, Strategy and Innovation at Teva. Mr. Wright is the founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center, where he previously served as Director. He is a current a member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board. Mr. Wright has served in executive leadership roles at several pharmaceutical firms, including Covidien, Elan, and DuPont Merck. He holds a B.Sc. from The Ohio State University.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Ed was named president & chief executive officer of Owens & Minor, effective March 7, 2019, and was appointed to the board of directors at the same time. Prior to that, Ed served as an independent consultant and advisor in the healthcare, life science and distribution industries since January 2016. From January 2000 through April 2015, he served in various roles of increasing responsibility at Thermo Fisher Scientific, a $17 billion manufacturer and supplier of a range of products to the research, healthcare, industrial and safety markets, including most recently as chief commercial officer & senior vice president. Before joining Thermo Fisher Scientific, Ed spent eight years at TRW Inc., in a variety of finance roles and three years with PricewaterhouseCoopers as an auditor.

Kevin serves as the fifth Chairman and CEO at Stryker since it was founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon. Stryker is a leading medical technology company with over 40,000 employees. Kevin was born in India, grew up in Canada, and has lived and worked in four countries and four industries. He is the current chair of AdvaMed (Med-Tech trade association) and is a member of the Business Roundtable and Business Council. He is also active with community boards.

John F. Sheridan has served as our President and Chief Executive Officer since March 2019 and as a member of our Board of Directors since June 2019. Prior to joining our company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation (NASDAQ: VOLC), a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.